Severe Spontaneous Cases of Bisphosphonate-Related Osteonecrosis of the Jaws

Journal of Oral and Maxillofacial Surgery

Volumn 65, Issue 8, 2007, Pages 1650-1654

  Herbozo, Percival J ^a   Briones, Daniel L ^b   Ferres, Alvaro J ^a   Torrealba, Ramón L ^a  

^a Department of Oral and Maxillofacial Surgery   (Chile)

^b UNIVERSIDAD MAYOR   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENALAPRIL; EXEMESTANE; GLIBENCLAMIDE; PACLITAXEL; TAMOXIFEN; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOMYELITIS;

AGED; AGED, 80 AND OVER; ALVEOLAR PROCESS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MANDIBULAR DISEASES; MAXILLARY DISEASES; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; SEVERITY OF ILLNESS INDEX;

EID: 34447562687     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2007.03.021     Document Type: Article

References (19)

1. Wang J., Goodger N.M., and Pogrel M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61 (2003) 1104
2. Ruggiero S.L., Mehrotra B., and Rosenberg T.J. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
3. Rodan G.A., and Fleisch H.A. Bisphosphonates: Mechanisms of action. J Clin Invest 97 (1996) 2692
4. Kyle R.A. The role of bisphosphonates in multiple myeloma. Ann Intern Med 132 (2000) 734
5. Sauty A., Pecherstorfer M., Zimmer-Roth I., et al. Interleukin-6 and tumor necrosis factor levels after bisphosphonate treatment in vitro and in patients with malignancy. Bone 18 (1996) 133
6. Berenson J.R., Lichtenstein A., Porter L., et al., Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334 (1996) 488
7. Hortobagyi G.N., Theriault R.L., Porter L., et al., Protocol 19 Aredia Breast Cancer Study Group. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335 (1996) 1785
8. Theriault R.L., Lipton A., Hortobagyi G.N., et al., Protocol 18 Aredia Breast Cancer Study Group. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. J. Clin Oncol 17 (1999) 846
9. Fitton A., and McTavish D. Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41 (1991) 289
10. Geddes A.D., Sharyn M., Ebetino F.H., et al. Bisphosphonates: Structure-activity relationships and therapeutic implications. In: Heersche J.N., and Kanis J.A. (Eds). Bone and Mineral Research (1994), Elsevier Science, Amsterdam 256
11. Mundy G.R., Yoneda T., and Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironment. Semin Oncol 28 (2001) 35
12. Santini D., Vicenzi B., Avvisati, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8 (2002) 1080
13. Santini D., Vicenzi B., and Dicuonzo G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9 (2003) 2893
14. Mashiba T., Hirano T., Turner C.H., et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 5 (2001) 613
15. Yamamoto Y., Toi M., Kondo S., et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2 (1996) 821
16. George D. Platelet-derived growth factor receptors: A therapeutic target in solid tumors. Semin Oncol 28 (2001) 27
17. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339 (1998) 357
18. Saarto T., Blomqvist C., Virkkunen P., et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19 (2001) 10
19. Paterson A.H. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer (Phila) 88 (2000) 3038